The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Cognitive Function in a Randomized Trial of Evolocumab
Open accessAbstract
Background Findings from clinical trials of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors have led to concern that these drugs or the low levels of low-density lipoprotein (LDL) cholesterol that result from their use are associated with cognitive deficits. Methods In a subgroup of patients from a randomized, placebo-controlled trial of evolocumab added to statin therapy, we prospectively assessed cognitive function using the Cambridge Neuropsychological Test Automated Battery. The primary end point was the score on the spatial working memory strategy index of executive function (scores range from 4 to 28, with lower scores indicating a more efficient use of strategy and planning). Secondary end points were the scores for working memory (scores range from 0 to 279, with lower scores indicating fewer errors), episodic memory (scores range from 0 to 70, with lower scores indicating fewer errors), and psychomotor speed (scores range from 100 to 5100 msec, with faster times representing better performance). Assessments of cognitive function were performed at baseline, week 24, yearly, and at the end of the trial. The primary analysis was a noninferiority comparison of the mean change from baseline in the score on the spatial working memory strategy index of executive function between the patients who received evolocumab and those who received placebo; the noninferiority margin was set at 20% of the standard deviation of the score in the placebo group. Results A total of 1204 patients were followed for a median of 19 months; the mean (±SD) change from baseline over time in the raw score for the spatial working memory strategy index of executive function (primary end point) was -0.21±2.62 in the evolocumab group and -0.29±2.81 in the placebo group (P<0.001 for noninferiority; P=0.85 for superiority). There were no significant between-group differences in the secondary end points of scores for working memory (change in raw score, -0.52 in the evolocumab group and -0.93 in the placebo group), episodic memory (change in raw score, -1.53 and -1.53, respectively), or psychomotor speed (change in raw score, 5.2 msec and 0.9 msec, respectively). In an exploratory analysis, there were no associations between LDL cholesterol levels and cognitive changes. Conclusions In a randomized trial involving patients who received either evolocumab or placebo in addition to statin therapy, no significant between-group difference in cognitive function was observed over a median of 19 months. (Funded by Amgen; EBBINGHAUS ClinicalTrials.gov number, NCT02207634 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Trials of PCSK9 inhibitors in cardiovascular populations consistently showed substantial reductions in LDL cholesterol without negative cognitive effects [11,22].”
From The Roles of PCSK9 in Alzheimer’s Disease: A Systematic Review of Clinical, Genetic, and Preclinical Evidence (2025) · cites this paper as [22]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“an anti-PCSK9 antibody study observed no significant between-group difference in cognitive function over a median of 19 months [66].”
From PCSK9 acts as a key regulator of Aβ clearance across the blood–brain barrier (2022) · cites this paper as [66]
The cited source says what the claim attributes to it.
In the citing paper
“large cardiovascular trials of PCSK9 antibodies such as evolocumab have not demonstrated cognitive harm10,43”
From Small-molecule PCSK9 inhibition enhances BBB amyloid-β clearance and suppresses microglial inflammation in Alzheimer’s disease models (2026) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“In addition, no change in cognitive function has been reported in studies with the addition of ezetimibe (119) or PCSK9 inhibitors (121,170) to statin therapy, including among individuals treated to very low LDL cholesterol levels.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [170]
The cited source says what the claim attributes to it.
In the citing paper
“In addition, no change in cognitive function has been reported in studies with the addition of ezetimibe (112) or PCSK9 monoclonal antibodies (115,164) to statin therapy, including among individuals treated to very low LDL cholesterol levels.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [164]
The cited source says what the claim attributes to it.
In the citing paper
“Our findings are in line with data from PCSK9 inhibitor clinical trials (Giugliano et al., 2017; Mannarino et al., 2018; Gencer et al., 2020; Ray et al., 2020) and from observations that people carrying loss-of-function mutations of the PCSK9 gene have no signs of neurological defects (Cohen et al., 2005, 2006; Zhao et al., 2006; Hooper et al., 2007; Mefford et al., 2018).”
From PCSK9 deficiency alters brain lipid composition without affecting brain development and function (2023) · cites this paper as Giugliano et al., 2017
In the citing paper
“The absolute benefit from statin treatment was lower in people in primary prevention, who are typically at lower risk [36,38,214,215].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [215]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Self-citationEzetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citationEfficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Self-citationEfficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
Self-citationPlanning and spatial working memory following frontal lobe lesions in man
Owen, A. M., Downes, J. J., Sahakian, B. J., Polkey, C. E., & Robbins, T. W. (1990) · Neuropsychologia · doi:10.1016/0028-3932(90)90137-d · Cited by 1,284
SAHAKIAN, B. J., MORRIS, R. G., EVENDEN, J. L., HEALD, A., LEVY, R., PHILPOT, M., & ROBBINS, T. W. (1988) · Brain · doi:10.1093/brain/111.3.695 · Cited by 666
The measurement of everyday cognition (ECog): Scale development and psychometric properties.
Farias, S. T., Mungas, D., Reed, B., Cahn, D. A., Jagust, W. J., Baynes, K., & DeCarli, C. S. (2008) · Neuropsychology · doi:10.1037/0894-4105.22.4.531 · Cited by 665
Robbins, T. W., James-Galton, M., Owen, A. M., Sahakian, B. J., Lawrence, A. D., McInnes, L., & Rabbitt, P. (1998) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617798455073 · Cited by 629
Schmermund, A., Möhlenkamp, S., Stang, A., Grönemeyer, D. H. W., Seibel, R. M. M., Hirche, H., Mann, K., Siffert, W., Lauterbach, K. W., Siegrist, J., et al. (2002) · American Heart Journal · doi:10.1067/mhj.2002.123579 · Cited by 582
Flagged first, then by citations
Research works printed but not linked: 1
- Jessup C. Cambridge Cognition awarded FDA marketing clearance for Cantab mobile. FDA News. January 26, 2017 (http://www.fdanews.com/articles/180219-cambridge-cognition-awarded-fda-marketing-clearance-for-cantab-mobile).
Cited by
Sorted by citations
Items 101–200 of 493
Janik, M. J., Urbach, D. V., van Nieuwenhuizen, E., Zhao, J., Yellin, O., Baccara-Dinet, M. T., Pordy, R., & Manvelian, G. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.06.913 · Cited by 51
Current Options and Future Perspectives in the Treatment of Dyslipidemia
Muscoli, S., Ifrim, M., Russo, M., Candido, F., Sanseviero, A., Milite, M., Luozzo, M. D., Marchei, M., & Sangiorgi, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164716 · Cited by 52
Feng, Z., Li, X., Tong, W. K., He, Q., Zhu, X. L., Xiang, X., & Tang, Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.894685 · Cited by 53
Meta‐analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD
Talasaz, A. H., Ho, A. (., Bhatty, F., Koenig, R. A., Dixon, D. L., Baker, W. L., & Van Tassell, B. W. (2021) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2635 · Cited by 48
Patti, G., Spinoni, E. G., Grisafi, L., Mehran, R., & Mennuni, M. G. (2022) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvac049 · Cited by 52
In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia
Vafai, S. B., Täubel, J., Ashdown, T., Patel, R. S., Diamondali, S., Cegla, J., Soran, H., Bashir, B., Abitbol, A., Gaudet, D., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2601283 · Cited by 54
PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results?
Mannarino, M. R., Sahebkar, A., Bianconi, V., Șerban, M.-C., Banach, M., & Pirro, M. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.05.012 · Cited by 48
Kalra, D. K., Vijayaraghavan, K., Sikand, G., Desai, N. R., Joshi, P. H., Mehta, A., Karmally, W., Vani, A. K., Sitafalwalla, S. J., Puri, R., et al. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.03.007 · Cited by 50
Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data
Strilchuk, L. M., Fogacci, F., & Cicero, A. F. G. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1620730 · Cited by 48
Proprotein convertase subtilisin/kexin type 9 and lipid metabolism
Spolitu, S., Dai, W., Zadroga, J. A., & Özcan, L. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000601 · Cited by 51
Oyama, K., Giugliano, R. P., Blazing, M. A., Park, J., Tershakovec, A. M., Sabatine, M. S., Cannon, C. P., & D, E. B. M. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.08.011 · Cited by 46
Self-citationKEECH, A. C., Oyama, K., Sever, P., Tang, M., Murphy, S. A., Hirayama, A., Lu, C., Tay, L., DEEDWANIA, P. C., Siu, C., et al. (2021) · Circulation Journal · doi:10.1253/circj.cj-20-1051 · Cited by 46
Self-citationMefford, M. T., Rosenson, R. S., Cushman, M., Farkouh, M. E., McClure, L. A., Wadley, V. G., Irvin, M. R., Bittner, V., Safford, M. M., Somaratne, R., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.029785 · Cited by 44
Risk of neuropsychiatric adverse effects of lipid-lowering drugs: a mendelian randomization study
Alghamdi, J., Matou-Nasri, S., Alghamdi, F., Alghamdi, S., Alfadhel, M., & Padmanabhan, S. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy060 · Cited by 44
PCSK9 inhibitors and cardiovascular outcomes
Steffens, D., Bramlage, P., Scheeff, C., Kašner, M., Hassanein, A., Friebel, J., & Rauch‐Kröhnert, U. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1677604 · Cited by 46
di Mauro, G., Zinzi, A., Scavone, C., Mascolo, A., Gaio, M., Sportiello, L., Ferrajolo, C., Rafaniello, C., Rossi, F., & Capuano, A. (2020) · Drug Safety · doi:10.1007/s40264-020-01021-3 · Cited by 45
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
Schmidt, A. F., Holmes, M. V., Preiss, D., Swerdlow, D. I., Denaxas, S., Fatemifar, G., Faraway, R., Finan, C., Lumbers, R. T., Henry, A., et al. (2019) · BMC Cardiovascular Disorders · doi:10.1186/s12872-019-1187-z · Cited by 41
Gunta, S. P., O’Keefe, J. H., O’Keefe, E. L., & Lavie, C. J. (2023) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2023.02.007 · Cited by 44
Khoury, P. E., Elbitar, S., Ghaleb, Y., Khalil, Y. A., Varret, M., Boileau, C., & Abifadel, M. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0684-8 · Cited by 46
Novel Therapeutic Targets for Managing Dyslipidemia
Sathiyakumar, V., Kapoor, K., Jones, S. R., Banach, M., Martin, S. S., & Toth, P. P. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.06.001 · Cited by 42
Human Genomics and Drug DevelopmentPreprint
Schmidt, A. F., Hingorani, A. D., & Finan, C. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a039230 · Cited by 40
PCSK9 concentrations in cerebrospinal fluid are not specifically increased in Alzheimer’s disease
Courtemanche, H., Bigot, E., Pichelin, M., Guyomarch, B., Boutoleau-Bretonnière, C., Le May, C., Derkinderen, P., & Cariou, B. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170993 · Cited by 39
Harnessing RNA Interference for Cholesterol Lowering: The Bench‐to‐Bedside Story of Inclisiran
Wilkinson, M. J., Bajaj, A., Brousseau, M. E., & Taub, P. R. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032031 · Cited by 37
Reijman, M. D., Schweizer, A., Peterson, A. L. H., Bruckert, E., Stratz, C., Defesche, J. C., Hegele, R. A., & Wiegman, A. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac025 · Cited by 37
Garwood, C. L., Cabral, K. P., Brown, R., & Dixon, D. L. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.4635 · Cited by 45
Banach, M., Burchardt, P., Chlebus, K., Dobrowolski, P., Dudek, D., Dyrbuś, K., Gąsior, M., Jankowski, P., Jozwiak, J. J., Kłosiewicz−Latoszek, L., et al. (2021) · Diagnostyka Laboratoryjna · doi:10.5604/01.3001.0015.4805 · Cited by 36
Bohula, E. A., Marston, N., Ruzza, A., Murphy, S. A., Ferrari, G. M. D., Díaz, R., Leiter, L. A., Elliott‐Davey, M., Wang, H., Bhatia, A. K., et al. (2023) · American Heart Journal · doi:10.1016/j.ahj.2023.12.004 · Cited by 36
Self-citationPCSK9 in cholesterol metabolism: from bench to bedside
Reiss, A. B., Shah, N. B., Muhieddine, D., Zhen, J., Yudkevich, J., Kasselman, L. J., & DeLeon, J. R. (2018) · Clinical Science · doi:10.1042/cs20180190 · Cited by 35
Safety and Tolerability of PCSK9 Inhibitors: Current Insights
Kosmas, C. E., Skavdis, A., Sourlas, A., Papakonstantinou, E. J., Genao, E. P., Uceta, R. E., & Guzman, E. (2020) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s288831 · Cited by 53
Lipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Practice
Rossi, M., Fabris, E., Barbisan, D., Massa, L., & Sinagra, G. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00497-3 · Cited by 35
Zafrir, B., & Jubran, A. (2018) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12439 · Cited by 37
Residual risks and evolving atherosclerotic plaques
Noothi, S. K., Ahmed, M. R., & Agrawal, D. K. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04689-0 · Cited by 37
Larsen, L. E., Stoekenbroek, R. M., Kastelein, J. J. P., & Holleboom, A. G. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.312028 · Cited by 34
Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature
Schonck, W. A. M., Stroes, E. S. G., Hovingh, G. K., & Reeskamp, L. F. (2024) · Drugs · doi:10.1007/s40265-024-01995-9 · Cited by 34
Coming Back to Physiology: Extra Hepatic Functions of Proprotein Convertase Subtilisin/Kexin Type 9
Schlüter, K., Wolf, A., & Schreckenberg, R. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.598649 · Cited by 35
PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance
Jia, X., Rifai, M. A., Saeed, A., Ballantyne, C. M., & Virani, S. S. (2022) · Vascular Health and Risk Management · doi:10.2147/vhrm.s275739 · Cited by 34
PCSK9 inhibitors for acute coronary syndrome: the era of early implementation
Chen, H., & Chen, X. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1138787 · Cited by 32
Lee, J. S., O’Connell, E. M., Pacher, P., & Lohoff, F. W. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081758 · Cited by 31
Ying, H., Wang, J., Shen, Z., Wang, M., & Zhou, B. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07045-2 · Cited by 31
Cognitive Function in a Randomized Trial of Evolocumab
Calabrò, P., Gragnano, F., & Pirro, M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1712102 · Cited by 31
Jones, J. E., Tang, K. S., Barseghian, A., & Wong, N. D. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12237432 · Cited by 34
Gaudet, D., Langslet, G., Gidding, S. S., Luirink, I. K., Ruzza, A., Kurtz, C. E., Lu, C., Somaratne, R. M., Raal, F. J., & Wiegman, A. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.05.007 · Cited by 30
Self-citationCybulska, B., Kłosiewicz−Latoszek, L., Penson, P. E., Nabavi, S. M., Lavie, C. J., & Banach, M. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.12.008 · Cited by 30
Interpreting the Findings From the Recent PCSK9 Monoclonal Antibody Cardiovascular Outcomes Trials
Wong, N. D., & Shapiro, M. D. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00014 · Cited by 29
Efficacy and safety of PCSK9 monoclonal antibodies: an evidence-based review and update
Kaddoura, R., Orabi, B., & Salam, A. M. (2020) · Journal of Drug Assessment · doi:10.1080/21556660.2020.1801452 · Cited by 31
New and emerging lipid-modifying drugs to lower LDL cholesterol
Kosmas, C. E., Pantou, D., Sourlas, A., Papakonstantinou, E. J., Uceta, R. E., & Guzman, E. (2021) · Drugs in Context · doi:10.7573/dic.2021-8-3 · Cited by 32
Safety of Statins and Nonstatins for Treatment of Dyslipidemia
Newman, C. B. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.01.004 · Cited by 32
Furtado, R. H. M., & Giugliano, R. P. (2020) · Cardiology and Therapy · doi:10.1007/s40119-020-00163-w · Cited by 29
Self-citationYu, S., Jin, J., Chen, Z., & Luo, X. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01369-6 · Cited by 28
PCSK9 is Increased in Cerebrospinal Fluid of Individuals With Alcohol Use Disorder
Lee, J. S., Rosoff, D. B., Luo, A. C., Longley, M. J., Phillips, M. J., Charlet, K., Muench, C., Jung, J., & Lohoff, F. W. (2019) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.14039 · Cited by 28
Therapeutic strategy for atherosclerosis based on bone-vascular axis hypothesis
Kim, J., Lee, W. S., & Kim, J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107436 · Cited by 28
A Clinical Guide to Combination Lipid-Lowering Therapy
Russell, C. E., Sheth, S., & Jacoby, D. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0721-2 · Cited by 27
Loss-of-function PCSK9 mutations are not associated with Alzheimer disease
Paquette, M., Saavedra, Y. G. L., Poirier, J., Théroux, L., Dea, D., Baass, A., & Dufour, R. (2018) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988718764330 · Cited by 26
Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?
Corsini, A., Ginsberg, H. N., & Chapman, M. J. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108812 · Cited by 27
Lipid-Lowering Therapy after Acute Coronary Syndrome
Pogran, E., Burger, A. L., Zweiker, D., Kaufmann, C. C., Muthspiel, M., Rega‐Kaun, G., Wenkstetten-Holub, A., Wojta, J., Drexel, H., & Huber, K. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13072043 · Cited by 27
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation
Goodman, S. G., Steg, P. G., Szarek, M. J., Bhatt, D. L., Bittner, V., Díaz, R., Harrington, R. A., Jukema, J. W., White, H. D., Zeiher, A. M., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae025 · Cited by 27
Long-Term Cognitive Safety of Achieving Very Low LDL Cholesterol with Evolocumab
Zimerman, A., O’Donoghue, M. L., Ran, X., Im, K., Ott, B. R., Mach, F., Zavitz, K. H., Kurtz, C. E., Monsalvo, M. L., Wang, B., et al. (2024) · NEJM Evidence · doi:10.1056/evidoa2400112 · Cited by 25
Self-citationRelationship between Lipoprotein (a) and cognitive function – Results from the Berlin Aging Study II
Rohr, F., Bucholtz, N., Toepfer, S., Norman, K., Spira, D., Steinhagen‐Thiessen, E., Lill, C. M., Bertram, L., Demuth, I., Buchmann, N., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-66783-3 · Cited by 26
Bjornsson, E., Gunnarsdottir, K., Halldorsson, G. H., Sigurdsson, A., Arnadottir, G. A., Jonsson, H., Olafsdottir, E. F., Niehus, S., Kehr, B., Sveinbjörnsson, G., et al. (2021) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.120.003029 · Cited by 23
The effect of PCSK9 inhibitors on brain stroke prevention: A systematic review and meta-analysis
Qin, J., Liu, L., Su, X. D., Wang, B. B., Fu, B. S., Cui, J., & Liu, X. Y. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.03.026 · Cited by 26
Elevated HDL Levels Linked to Poorer Cognitive Ability in Females With Parkinson’s Disease
Bakeberg, M. C., Gorecki, A. M., Kenna, J. E., Jefferson, A., Byrnes, M. L., Ghosh, S., Horne, M. K., McGregor, S., Stell, R., Walters, S., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.656623 · Cited by 25
Li, X., Yuan, X., Pang, L., Zhang, S., Li, Y., Huang, X., Fan, X., & Song, X. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114582 · Cited by 25
Neurological effects of proprotein convertase subtilisin/kexin type 9 inhibitors: direct comparisons
Bajaj, N. S., Patel, N., Kalra, R., Ahmad, A., Venkatraman, A., Arora, G., & Arora, P. K. (2017) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcx037 · Cited by 25
Dixon, D. L., Pamulapati, L. G., Bucheit, J. D., Sisson, E. M., Smith, S. R., Kim, C. J., Wohlford, G. F., & Pozen, J. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0778-6 · Cited by 25
Efficacy and safety of PCSK9 monoclonal antibodies
Iqbal, Z., Dhage, S. S., Mohamad, J. B., Abdel-Razik, A. E. S., Donn, R. P., Malik, R. A., Ho, J. H., Liu, Y., Adam, S., Isa, B., et al. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1681395 · Cited by 26
The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?
Miname, M. H., Rocha, V. Z., & Santos, R. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00936-1 · Cited by 25
Best Treatment Strategies With Statins to Maximize the Cardiometabolic Benefits
Cho, K. I., Sakuma, I., Sohn, I. S., Hayashi, T., Shimada, K., & Koh, K. K. (2018) · Circulation Journal · doi:10.1253/circj.cj-17-1445 · Cited by 23
Atualização da Diretriz Brasileira de Hipercolesterolemia Familiar – 2021
Izar, M. C. D. O., Rocha, V. Z., Bertolami, A., Santos, R. D., Lottenberg, A. M., Assad, M. H. V., Saraiva, J. F. K., Chacra, A. P. M., Martinez, T. L. D. R., Bahia, L., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210788 · Cited by 35
Zhang, Q., Liu, Z., Wang, Q., & Li, X. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01645-7 · Cited by 23
Castilla‐Guerra, L., Fernández‐Moreno, M. D. C., Jiménez, D. L., & Rico, M. Á. (2019) · Current Treatment Options in Neurology · doi:10.1007/s11940-019-0563-4 · Cited by 23
Kim, E. J., & Wierzbicki, A. S. (2020) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622320924569 · Cited by 22
Statins in High Cardiovascular Risk Patients: Do Comorbidities and Characteristics Matter?
Rossini, E., Biscetti, F., Rando, M. M., Nardella, E., Cecchini, A. L., Nicolazzi, M. A., Covino, M., Gasbarrini, A., Massetti, M., & Flex, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169326 · Cited by 25
Albuquerque, E. L., Fulco, U. L., Caetano, E. W. S., & Freire, V. N. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108774956.011 · Cited by 21
Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?
Filippatos, T. D., Christopoulou, E. C., & Elisaf, M. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000523 · Cited by 22
PCSK9 Inhibitors: Clinical Relevance, Molecular Mechanisms, and Safety in Clinical Practice
Ferrari, F., Stein, R., Motta, M. T., & Moriguchi, E. H. (2019) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20190029 · Cited by 22
Armario, P., Brotons, C., Elosúa, R., de Leciñana, M. A., Castro, A., Clarà, A. B. I., Cortés, O., Rodríguez, Á. D., Herranz, M., Justo, S., et al. (2021) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2021.02.001 · Cited by 20
The Role of PCSK9 Inhibitors in the Treatment of Hypercholesterolemia
Patel, R. S., Scopelliti, E. M., & Olugbile, O. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018771670 · Cited by 21
Lipid management in ACS: Should we go lower faster?
Gencer, B., & Mach, F. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.871 · Cited by 21
Self-citationRaccah, B. H., Yanovsky, A., Treves, N., Rotshild, V., Renoux, C., Danenberg, H. D., Eliaz, R., & Matok, I. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.04.025 · Cited by 21
Primary prevention statin therapy in older adults
Nanna, M. G., Abdullah, A., Mortensen, M. B., & Návar, A. M. (2022) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001003 · Cited by 28
Psychiatric disorders associated with PCSK9 inhibitors: A real‐world, pharmacovigilance study
Deng, Z., Liu, J., Gong, H., Cai, X., Han, X., & Gao, W. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14522 · Cited by 20
LDL cholesterol: How low to go?
Packard, C. J. (2017) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2017.12.011 · Cited by 20
New Insights in the Control of Low-Density Lipoprotein Cholesterol to Prevent Cardiovascular Disease
Katzmann, J. L., & Laufs, U. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1159-z · Cited by 19
Offer, A. R., Arnold, M., Clarke, R., Bennett, D., Bowman, L. J., Bulbulia, R. A., Haynes, R., Li, J., Hopewell, J. C., Landray, M., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.0223 · Cited by 20
Ntaios, G., & Milionis, H. J. (2019) · International Journal of Stroke · doi:10.1177/1747493019851283 · Cited by 20
The year in cardiovascular medicine 2021: dyslipidaemia
Tokgözoğlu, L. S., Orringer, C. E., Ginsberg, H. N., & Catapano, A. L. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab875 · Cited by 22
Recomendaciones preventivas cardiovasculares. Actualización PAPPS 2020
Orozco‐Beltrán, D., Cuixart, C. B., Sánchez, J. J. A., Banegas, J. R., Cuenca, A. M. C., Gil-Guillén, V. F., Rioboó, E. M., & Pérez, J. N. (2020) · Atención Primaria · doi:10.1016/j.aprim.2020.08.002 · Cited by 24
Schwartz, G. G., & Giugliano, R. P. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000830 · Cited by 19
Self-citationMolecular aspects of hypercholesterolemia treatment: current perspectives and hopes
Ahangari, N., Ghayour‐Mobarhan, M., Sahebkar, A., & Pasdar, A. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1457795 · Cited by 20
PCSK9 inhibitors and LDL reduction: pharmacology, clinical implications, and future perspectives
Fitzgerald, G., & Kiernan, T. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1497975 · Cited by 21
Cognitive function with evolocumab in pediatric heterozygous familial hypercholesterolemia
Gaudet, D., Ruzza, A., Bridges, I. M., Maruff, P. T., Schembri, A. J., Hamer, A. W., Mach, F., Bergeron, J., Gaudet, I., St‐Pierre, J., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.07.005 · Cited by 18
Self-citationJia, X., Liu, J., Mehta, A., Ballantyne, C. M., & Virani, S. S. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07082-x · Cited by 18
Sagris, D., Ntaios, G., Georgiopoulos, G. A., Kakaletsis, N., Elisaf, M., Katsiki, N., Korompoki, E., Kypreos, K. E., Boutari, C., Bilianou, H. I., et al. (2020) · International Journal of Stroke · doi:10.1177/1747493020971970 · Cited by 18
Long-term levels of LDL-C and cognitive function: the CARDIA study
Mefford, M. T., Chen, L., Lewis, C. E., Muntner, P., Sidney, S., Launer, L. J., Monda, K. L., Ruzza, A., Kassahun, H., Rosenson, R. S., et al. (2021) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617721000059 · Cited by 15
Recomendaciones preventivas cardiovasculares. Actualización PAPPS 2022
Orozco‐Beltrán, D., Cuixart, C. B., Banegas, J. R., Gil-Guillén, V. F., Cuenca, A. M. C., Rioboó, E. M., Baldó, A. J., Vicuña, J., & Pérez, J. N. (2022) · Atención Primaria · doi:10.1016/j.aprim.2022.102444 · Cited by 64
Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review
Farnier, M. (2017) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2017.1409115 · Cited by 17
PCSK9 deficiency alters brain lipid composition without affecting brain development and function
Pärn, A., Olsen, D., Tuvikene, J., Kaas, M., Borisova, E., Bilgin, M., Elhauge, M., Vilstrup, J., Madsen, P., Ambrozkiewicz, M. C., et al. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1084633 · Cited by 16
Vigne, S., Duc, D., Peter, B., Rebeaud, J., Yersin, Y., Ruiz, F., Bressoud, V., Collet, T.-H., & Pot, C. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02409-x · Cited by 16
Burger, A. L., Pogran, E., Muthspiel, M., Kaufmann, C. C., Jäger, B., & Huber, K. (2022) · Biomedicines · doi:10.3390/biomedicines10050970 · Cited by 17
Gouni‐Berthold, I., Schwarz, J., & Berthold, H. K. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01053-3 · Cited by 16
Metadata
- Authors
- Giugliano, R. P., Mach, F., Zavitz, K., Kurtz, C., Im, K., Kanevsky, E., Schneider, J., Wang, H., Keech, A., Pedersen, T. R., Sabatine, M. S., Sever, P. S., Robinson, J. G., Honarpour, N., Wasserman, S. M., & Ott, B. R.
- Affiliations
- Oslo University Hospital (NO)
- University of Iowa (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-08-17
- Volume
- 377
- Issue
- 7
- Pages
- 633-643
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2746224452
- Cited by
- 492
- References
- 29
- Citations by year
- 2026: 36 · 2025: 39 · 2024: 35 · 2023: 41 · 2022: 46 · 2021: 63 · 2020: 68 · 2019: 63 · 2018: 75 · 2017: 23
- FWCI
- 64.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- NORA - Norwegian Open Research Archives (submittedVersion, other-oa)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0513-10059)
- University of California, Davis
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- evolocumab, PCSK9 inhibitors, cognitive function, executive function, spatial working memory, working memory, episodic memory, psychomotor speed, LDL cholesterol, statin therapy, non-inferiority, cognitive safety, hypercholesterolemia, Alzheimer's disease risk, dementia risk, cognitive decline
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Anticholesteremic Agents, Cognition, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Cholesterol, LDL, Male, Memory, Middle Aged, Prospective Studies, Psychological Tests, Self-Assessment, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
